Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Vincent Rijckborst; Bettina E. Hansen; Peter Ferenci; Maurizia R. Brunetto; Fehmi Tabak; Yilmaz Cakaloglu; A. Galeota Lanza; Vincenzo Messina; Claudio Iannacone; Benedetta Massetto; Loredana Regep; Massimo Colombo; Harry L A Janssen; Pietro Lampertico

doi:10.1016/j.jhep.2011.12.007

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Vincent Rijckborst, Bettina E. Hansen, Peter Ferenci, Maurizia R. Brunetto, Fehmi Tabak, Yilmaz Cakaloglu, A. Galeota Lanza, Vincenzo Messina, Claudio Iannacone, Benedetta Massetto, Loredana Regep, Massimo Colombo, Harry L A Janssen, Pietro Lampertico

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

Original language	English
Pages (from-to)	1006-1011
Number of pages	6
Journal	Journal of Hepatology
Volume	56
Issue number	5
DOIs	https://doi.org/10.1016/j.jhep.2011.12.007
Publication status	Published - May 2012

Keywords

HBV genotype
HBV therapy
Immunomodulator
Nucleos(t)ide analogues
Peginterferon
Quantitative HBsAg

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.jhep.2011.12.007

Fingerprint Dive into the research topics of 'Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a'. Together they form a unique fingerprint.

Cite this

Rijckborst, V., Hansen, B. E., Ferenci, P., Brunetto, M. R., Tabak, F., Cakaloglu, Y., Lanza, A. G., Messina, V., Iannacone, C., Massetto, B., Regep, L., Colombo, M., Janssen, H. L. A., & Lampertico, P. (2012). Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. Journal of Hepatology, 56(5), 1006-1011. https://doi.org/10.1016/j.jhep.2011.12.007

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. / Rijckborst, Vincent; Hansen, Bettina E.; Ferenci, Peter; Brunetto, Maurizia R.; Tabak, Fehmi; Cakaloglu, Yilmaz; Lanza, A. Galeota; Messina, Vincenzo; Iannacone, Claudio; Massetto, Benedetta; Regep, Loredana; Colombo, Massimo; Janssen, Harry L A; Lampertico, Pietro.

In: Journal of Hepatology, Vol. 56, No. 5, 05.2012, p. 1006-1011.

Research output: Contribution to journal › Article › peer-review

Rijckborst, V, Hansen, BE, Ferenci, P, Brunetto, MR, Tabak, F, Cakaloglu, Y, Lanza, AG, Messina, V, Iannacone, C, Massetto, B, Regep, L, Colombo, M, Janssen, HLA & Lampertico, P 2012, 'Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a', Journal of Hepatology, vol. 56, no. 5, pp. 1006-1011. https://doi.org/10.1016/j.jhep.2011.12.007

Rijckborst, Vincent ; Hansen, Bettina E. ; Ferenci, Peter ; Brunetto, Maurizia R. ; Tabak, Fehmi ; Cakaloglu, Yilmaz ; Lanza, A. Galeota ; Messina, Vincenzo ; Iannacone, Claudio ; Massetto, Benedetta ; Regep, Loredana ; Colombo, Massimo ; Janssen, Harry L A ; Lampertico, Pietro. / Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. In: Journal of Hepatology. 2012 ; Vol. 56, No. 5. pp. 1006-1011.

@article{b4f1cd0ac2d545629d27be30ce40c8ba,

title = "Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a",

abstract = "Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with ",

keywords = "HBV genotype, HBV therapy, Immunomodulator, Nucleos(t)ide analogues, Peginterferon, Quantitative HBsAg",

author = "Vincent Rijckborst and Hansen, {Bettina E.} and Peter Ferenci and Brunetto, {Maurizia R.} and Fehmi Tabak and Yilmaz Cakaloglu and Lanza, {A. Galeota} and Vincenzo Messina and Claudio Iannacone and Benedetta Massetto and Loredana Regep and Massimo Colombo and Janssen, {Harry L A} and Pietro Lampertico",

year = "2012",

month = may,

doi = "10.1016/j.jhep.2011.12.007",

language = "English",

volume = "56",

pages = "1006--1011",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

AU - Rijckborst, Vincent

AU - Hansen, Bettina E.

AU - Ferenci, Peter

AU - Brunetto, Maurizia R.

AU - Tabak, Fehmi

AU - Cakaloglu, Yilmaz

AU - Lanza, A. Galeota

AU - Messina, Vincenzo

AU - Iannacone, Claudio

AU - Massetto, Benedetta

AU - Regep, Loredana

AU - Colombo, Massimo

AU - Janssen, Harry L A

AU - Lampertico, Pietro

PY - 2012/5

Y1 - 2012/5

N2 - Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

AB - Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

KW - HBV genotype

KW - HBV therapy

KW - Immunomodulator

KW - Nucleos(t)ide analogues

KW - Peginterferon

KW - Quantitative HBsAg

UR - http://www.scopus.com/inward/record.url?scp=84859734382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859734382&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.12.007

DO - 10.1016/j.jhep.2011.12.007

M3 - Article

C2 - 22245886

AN - SCOPUS:84859734382

VL - 56

SP - 1006

EP - 1011

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -